Explore 3 Stock Ideas & Industry Insights Download Free Report

Aridis Pharmaceuticals Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-16T21:00:00Z
VOLUME
10
Market Cap
0.01M

Momentum Score

…

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aridis Pharmaceuticals is a clinical-stage biopharmaceutical company developing antibody-based and inhaled therapeutics aimed at bacterial and respiratory infections. Long-term growth drivers include unmet need for treatments against antibiotic-resistant and hospital-acquired infections, ongoing clinical trial readouts and potential partnerships or licensing opportunities, and platform capabilities for targeted biologics. The company may benefit from positive clinical or regulatory milestones that could support development progress and external collaborations.
The most important investment risks are clinical and regulatory failure, limited operating history and cash runway that may require frequent financing, and low liquidity as a Pink-listed microcap.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
22.36M
Revenue Per Share
0.69
Gross Profit TTM
5.21M
Debt / Equity
-0.25
ROE
-
Net Debt
1.25M
ROCE
135.09%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.37M -43.19M -22.33M -29.68M -22.11M
Net income -30.75M -42.28M -22.33M -28.99M -22.11M
Selling general administrative 7.16M 7.31M 6.45M 6.03M 3.87M
Gross profit - 1.53M 1.00M 1.02M 2.76M
Reconciled depreciation 0.49M 0.43M 0.34M 0.34M 0.28M
Ebit -29.99M -43.71M -22.33M -29.43M -26.03M
Ebitda -29.51M -44.43M 31.47M -29.09M -25.75M
Depreciation and amortization 0.49M -0.72M 0.34M 0.34M 0.28M
Non operating income net other - - -0.01M -0.59M 2.01M
Operating income -29.99M -43.71M -22.40M -29.09M -24.12M
Other operating expenses 29.99M 43.71M 23.40M 30.11M 26.87M
Interest expense 0.38M -0.24M 0.00M 0.00M 0.42M
Interest income - - 0.08M 0.59M 0.38M
Net interest income -0.12M -0.24M 0.08M 0.36M 0.42M
Income tax expense 0.38M -0.91M -0.41M -0.69M 2.43M
Total revenue 0.00M 1.53M 1.00M 1.02M 2.76M
Total operating expenses 29.99M 43.71M 23.40M 30.11M 26.87M
Cost of revenue - - - - 23.00M
Total other income expense net -0.38M 0.52M 22.38M -0.59M 1.59M
Net income from continuing ops -30.37M -43.19M -22.33M -29.68M -22.11M
Net income applicable to common shares - -46.32M -22.33M -29.68M -23.46M
Preferred stock and other adjustments - - - - 1.36M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14.70M 26.80M 15.12M 27.97M 31.61M
Intangible assets 0.02M 0.02M 0.03M 0.03M 0.04M
Other current assets 5.51M 6.81M 6.88M 7.07M 2.45M
Total liab 38.93M 40.91M 23.80M 24.33M 5.30M
Total stockholder equity -24.23M -14.11M -8.68M 3.64M 26.31M
Deferred long term liab - 0.10M 0.09M 0.53M -
Other current liab 9.58M 6.57M 1.37M 2.97M 0.46M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -195.67M -165.29M -123.10M -100.77M -71.09M
Other liab - 1.28M 1.36M 5.00M -
Other assets - -2.31M -2.27M -1.60M 0.99M
Cash 4.88M 19.99M 8.23M 20.90M 24.24M
Total current liabilities 36.90M 33.35M 22.44M 19.33M 5.30M
Current deferred revenue 20.17M 20.84M 18.75M 14.60M 0.02M
Net debt 1.25M -14.01M -7.52M -20.90M -24.24M
Short term debt 4.84M 0.70M 0.44M - 2.49M
Short long term debt 4.30M 0.70M 0.44M - -
Short long term debt total 6.13M 5.98M 0.71M - -
Other stockholder equity 166.38M 151.18M 114.42M 104.40M 66.28M
Property plant equipment - 1.36M 1.26M 1.01M 1.27M
Total current assets 11.63M 26.80M 15.12M 27.97M 24.24M
Long term investments - - - 0.01M 0.96M
Net tangible assets - -13.13M -8.71M 3.60M 26.28M
Net receivables 1.24M 0.24M 0.37M 0.41M 1.66M
Long term debt - 5.28M 0.28M - -
Inventory - -0.24M -0.37M -0.41M -4.11M
Accounts payable 2.31M 5.24M 1.89M 1.75M 2.33M
Accumulated other comprehensive income 5.05M - - -0.82M -0.49M
Common stock total equity - - 0.00M 0.00M 0.00M
Retained earnings total equity - - -123.10M -100.77M -71.09M
Non currrent assets other 0.91M -1.38M -1.28M -1.05M 7.37M
Non current assets total 3.07M 2.31M 2.27M 1.60M 7.37M
Capital lease obligations 1.83M - - - -
Long term debt total - - 0.28M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.08M -0.53M -0.37M -0.17M -1.00M
Change to liabilities - 4.80M -0.08M -0.47M 2.10M
Total cashflows from investing activities - -0.53M -0.37M -0.17M -1.68M
Net borrowings - 5.00M 0.71M 0.71M 0.71M
Total cash from financing activities 14.78M 34.72M 8.68M 4.99M 25.09M
Change to operating activities - 5.58M -0.53M -2.55M -2.06M
Net income -30.37M -42.19M -22.33M -29.68M -22.11M
Change in cash -14.43M 11.25M -12.16M -3.34M -0.86M
Begin period cash flow 19.99M 8.73M 20.90M 24.24M 25.10M
End period cash flow 5.56M 19.99M 8.73M 20.90M 24.24M
Total cash from operating activities -29.13M -22.94M -20.48M -8.16M -24.27M
Issuance of capital stock 12.61M 29.71M 7.95M 4.96M 25.08M
Depreciation 0.49M 0.43M 0.34M 0.34M 0.28M
Other cashflows from investing activities - - - - -1.00M
Dividends paid - -4.13M - - 1.36M
Change to inventory - - - -2.55M -2.85M
Change to account receivables -1.00M 0.13M -0.14M 1.66M -1.66M
Sale purchase of stock - - 7.96M 4.99M 25.09M
Other cashflows from financing activities 3.97M 9.13M 0.73M 0.04M 1.37M
Change to netincome - 8.05M 2.14M 2.01M 0.03M
Capital expenditures 0.08M 0.53M 0.37M 0.17M 0.68M
Change receivables - - -0.14M 1.69M -1.66M
Cash flows other operating - - 0.37M 17.96M -2.91M
Cash and cash equivalents changes - - -12.16M -3.34M -0.86M
Change in working capital -1.30M 10.52M -0.62M 18.22M -2.52M
Stock based compensation 1.48M 2.25M 2.13M 2.01M 1.66M
Other non cash items 0.58M 6.78M 0.01M 0.95M -1.59M
Free cash flow -29.21M -23.47M -20.84M -8.33M -24.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ARDS
Aridis Pharmaceuticals Inc
-
-%
0.00 - 2.06 0.00 5.40 0.25 -0.87
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

983 University Avenue, Los Gatos, CA, United States, 95032

408 385 1742

37

Name Title Year Born
Dr. Vu L. Truong Ph.D. Founder, CEO, Chief Scientific Officer & Director 1964
Mr. Fred Kurland J.D., M.B.A. Chief Financial Officer 1951
Dr. Hasan Jafri M.D. Chief Medical Officer NA
Mr. Jeffrey J. Fessler Esq., J.D. Acting Gen. Counsel 1963
Dr. Eric J. Patzer Ph.D. Founder & Executive Chairman 1949
Dr. Hasan Jafri M.D. Chief Medical Officer 1967
Ms. Tamara S. Allen Vice President of Finance 1967
Mr. Jeffrey J. Fessler Esq., J.D. Acting General Counsel 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…